Pharma
Our involvement Print PDF

Knowledge of protein interactions is key for understanding the normal or pathological functions of normal or cancer cells.
This is why Hybrigenics applies its expertise in functional proteomics to the discovery and development of new treatments against cancer.

 

Hybrigenics starts phase 2 trial, Inecalcitol-CT2 , in hormone-refractory prostate cancer .

The first patient has been treated in France on November 7, 2007 at the European Hospital Georges Pompidou in Paris.
© 2008 hybrigenics